- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07265479
En studie för att undersöka säkerheten och effektiviteten av Tapinarof-kräm, 1% hos deltagare i åldrarna 3 månader till < 24 månader med atopisk dermatit (Adoring)
En randomiserad, dubbelblind, fordonkontrollerad (period 1) och öppen (period 2) fas 3-studie för att undersöka säkerheten och effekten av Tapinarof-kräm, 1 % hos pediatriska deltagare i åldern 3 månader till < 24 månader med atopisk dermatit
The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35209
- AllerVie Clinical Research
-
-
Arkansas
-
Bryant, Arkansas, Förenta staterna, 72022
- Dermatology Trial Associates
-
-
California
-
Los Angeles, California, Förenta staterna, 90045
- Dermatology Research Associates
-
Sacramento, California, Förenta staterna, 95815
- Integrative Skin Science and Research
-
San Diego, California, Förenta staterna, 92123
- Allergy and Asthma Medical Group and Research Center
-
Thousand Oaks, California, Förenta staterna, 91320
- Clinical Trials Research Institute
-
-
Colorado
-
Castle Rock, Colorado, Förenta staterna, 80109
- Clarity Dermatology
-
-
Florida
-
Boca Raton, Florida, Förenta staterna, 33486
- Skin Care Research, LLC.
-
Jacksonville, Florida, Förenta staterna, 32256
- APEX Clinical Trials
-
Wellington, Florida, Förenta staterna, 33449
- TruDerm Research
-
-
Georgia
-
Cumming, Georgia, Förenta staterna, 30040
- Cleaver Medical Group Dermatology, Inc
-
-
Idaho
-
Meridian, Idaho, Förenta staterna, 83646
- Ada West Research
-
-
Illinois
-
Skokie, Illinois, Förenta staterna, 60077
- Endeavor Health Clinical Trials Center
-
-
Indiana
-
Indianapolis, Indiana, Förenta staterna, 46250
- Dawes Fretzin Clinical Research Group, LLC
-
Plainfield, Indiana, Förenta staterna, 46168
- The Indiana Clinical Trials Center, PC
-
-
Kentucky
-
Bowling Green, Kentucky, Förenta staterna, 42104
- Equity Medical, LLC
-
-
Maryland
-
Rockville, Maryland, Förenta staterna, 20850
- Lawrence J Green, MD LLC
-
-
Michigan
-
Auburn Hills, Michigan, Förenta staterna, 48326
- Oakland Hills Dermatology
-
-
Minnesota
-
New Brighton, Minnesota, Förenta staterna, 55112
- Minnesota Clinical Study Center
-
-
Mississippi
-
Ridgeland, Mississippi, Förenta staterna, 39157
- SKY Integrative Medical Center
-
-
Missouri
-
Saint Joseph, Missouri, Förenta staterna, 64506
- MediSearch Clinical Trials
-
-
Nevada
-
Reno, Nevada, Förenta staterna, 89509
- Skin Cancer and Dermatology Institute
-
-
New York
-
Kew Gardens, New York, Förenta staterna, 11415
- Forest Hills Dermatology Group
-
New York, New York, Förenta staterna, 10012
- Bobby Buka MD, PC
-
The Bronx, New York, Förenta staterna, 10455
- Equity Medical, LLC
-
-
North Carolina
-
Chapel Hill, North Carolina, Förenta staterna, 27516
- The University of North Carolina Dermatology and Skin Cancer Center
-
-
Ohio
-
Fairborn, Ohio, Förenta staterna, 45324
- Dermatologists of Central States, LLC
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Förenta staterna, 73120
- Allergy Asthma and Clinical Research Center
-
-
Oregon
-
Portland, Oregon, Förenta staterna, 97210
- Oregon Dermatology and Research Center
-
Portland, Oregon, Förenta staterna, 97239
- Oregon Health & Science University
-
-
South Carolina
-
Charleston, South Carolina, Förenta staterna, 29425
- Medical University of South Carolina
-
North Charleston, South Carolina, Förenta staterna, 29420
- National Allergy and Asthma Research, LLC.
-
-
Texas
-
Bellaire, Texas, Förenta staterna, 77401
- The University of Texas Health Science Center at Houston
-
Dallas, Texas, Förenta staterna, 75230
- Dermatology Treatment and Research Center
-
Southlake, Texas, Förenta staterna, 76092
- Stryde Research - Epiphany Dermatology
-
-
Washington
-
Spokane, Washington, Förenta staterna, 99202
- Dermatology Specialists of Spokane
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada, T2J 7E1
- Dermatology Research Institute
-
Red Deer, Alberta, Kanada, T4P 1K4
- CARe Clinic (Central Alberta Research Clinic)
-
-
British Columbia
-
Surrey, British Columbia, Kanada, V3R 6A7
- Dr. Chih-Ho Hong Medical Inc.
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada, R3J 0S9
- Manitoba Allergy Research Inc.
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3K 5R3
- Maritime Dermatology
-
-
Ontario
-
Burlington, Ontario, Kanada, L7L 6W6
- Halton Pediatric Allergy
-
Hamilton, Ontario, Kanada, L8S 1G5
- Triple A Lab Inc.
-
Niagara Falls, Ontario, Kanada, L2H 1C4
- Allergy Research Canada Inc.
-
-
Saskatchewan
-
Regina, Saskatchewan, Kanada, S4V 1R9
- Dr. Rachel Asiniwasis Medical Professional Corporation
-
Saskatoon, Saskatchewan, Kanada, S7K 2C1
- Skinsense Medical Research
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Infants and toddlers born at term (≥37 weeks of gestational age) that are 3 months to <24 months of age at the Screening visit.
- Clinical diagnosis of atopic dermatitis (AD), AD covering >5% Body Surface Area (BSA) and validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of 2, 3 or 4
- Legal guardian or primary caregiver is willing and able to sign informed consent form before any study-related activities
- Legal guardian or primary caregiver is able and willing to adhere to protocol requirements
Exclusion Criteria:
- Significant neurological disorder or history of seizure
- Know clinically significant cardiac rhythm or cardiac disorder
- History of sudden infant death in a sibling
- Clinically significant chromosome abnormality
- History of or ongoing serious illness or medical, physical or psychiatric condition(s) that may interfere with the participant's participation
- Diseases that could cause pruritic and/or sleep disruption
- Immunocompromised
- Current chronic or acute infection requiring treatment
- Use of prohibited medication(s) or procedure(s)
- Use of prohibited medications by breastfeeding mother if breastfeeding participant
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Tapinarof cream
Tapinarof cream, 1%, applied topically once daily |
Tapinarof cream, 1%: Applied topically once daily to lesions on participant's skin during the Double-Blind period. During the Open-Label Period, it will be applied once daily to lesions, as needed.
Andra namn:
|
|
Placebo-jämförare: Vehicle cream
Vehicle cream is applied topically once daily for up to 8-weeks. |
Applied topically once daily to lesions on participant's skin during the Double-Blind period. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Percentage of participants who have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement from Baseline to Week 8
Tidsram: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is reported as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
|
Percentage of participants who enter with or achieve have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement at least once during the Open-Label Period
Tidsram: Baseline to the end of the Open-Label Period, up to 56 weeks.
|
The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint.. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is reported as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease. |
Baseline to the end of the Open-Label Period, up to 56 weeks.
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Percentage of participants with ≥ 75% improvement in Eczema Area and Severity Index (EASI) Score from Baseline to Week 8.
Tidsram: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
The EASI is a scoring system that takes into account the overall severity of disease based on lesion severity and the %BSA affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. The subject's scalp is excluded from this assessment. A higher EASI score represents more severe disease. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
|
Mean change in percentage of total body surface area (%BSA) affected from Baseline to Week 8
Tidsram: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
Assessment of %BSA is an estimate of the percentage of total involved skin with atopic dermatitis. Estimates were made using the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumbs together) represented approximately 1% of the total BSA. Body regions are assigned a specific number of handprints with associated percentages (Head and neck = 10% [10 handprints], upper extremities = 20% [20 handprints], trunk (including axillae and groin) = 30% [30 handprints], lower extremities, including buttocks, = 40% [40 handprints]). Estimates of the percent involvement of each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
|
Percentage of participants with ≥ 90% improvement in Eczema Area and Severity Index (EASI) score from Baseline to Week 8
Tidsram: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
Severity Index (EASI) score from Baseline to Week 8 Description: The EASI is a scoring system that takes into account the overall severity of disease based on lesion severity and the extent of percent body surface area affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent body surface area involved for each body region relative to the whole body. A higher EASI score represents more severe disease. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
|
Number of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Tidsram: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
TEAEs are AEs that started on or after the first dose of study medication. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
|
Number of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Tidsram: Baseline to the end of the Open-Label Period, up to 56 weeks
|
TEAEs are AEs that started on or after the first dose of study medication. |
Baseline to the end of the Open-Label Period, up to 56 weeks
|
|
Percentage of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Tidsram: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks .
|
TEAEs are AEs that started on or after the first dose of study medication. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks .
|
|
Percentage of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Tidsram: Baseline to the end of the Open-Label Period, up to 56 weeks.
|
TEAEs are AEs that started on or after the first dose of study medication. |
Baseline to the end of the Open-Label Period, up to 56 weeks.
|
|
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (overall)
Tidsram: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
|
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (overall)
Tidsram: Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
|
The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation. |
Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
|
|
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (sensitive areas)
Tidsram: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
|
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (sensitive areas)
Tidsram: Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
|
The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation. |
Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Clinical Lead Late-Stage Clinical Development, Organon and Co
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- OG0505-3104
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .